Future Pak offers to buy Theratechnologies for up to $255 million

WIXOM, Mich. - Future Pak, LLC has made a bid to acquire Theratechnologies Inc. (NASDAQ: THTX), a pharmaceutical company currently valued at $59.08 million in market capitalization, with a proposal that could value the company at up to $255 million. According to InvestingPro data, Theratechnologies maintains a "Good" financial health score despite operating with significant debt. The offer includes a cash payment of $205 million at closing and up to $50 million in additional payments tied to future profits of Theratechnologies' EGRIFTA® franchise.

The latest proposal, which remains on the table for Theratechnologies' Board of Directors, suggests a purchase price range of $3.51 to $4.50 per share. This price represents a premium of 164% to 238% over Theratechnologies' closing stock price of $1.33 on April 10, 2025. The offer aligns with analyst expectations, as InvestingPro shows a consensus target price of $3.88. Notably, the stock has experienced significant pressure, declining 26.52% year-to-date.

Future Pak's Chief Growth Officer, Nirav Patel, stated that the offer aims to present a flexible and attractive deal to Theratechnologies' shareholders, offering them significant upside potential. He emphasized the company's readiness for a constructive dialogue to reach a mutually beneficial agreement.

Despite Future Pak's efforts, which include multiple proposals offering a substantial premium, there has been limited engagement from Theratechnologies thus far. Future Pak remains hopeful that by making its intentions public, it will prompt Theratechnologies shareholders to consider the offer and compel the Board to seek the best possible outcome for its shareholders.

The proposed acquisition is not contingent on financing, as Future Pak has confirmed the backing of its strategic financial partner, Colbeck Capital Management. With the support of Bourne Partners Securities LLC as financial advisor and Honigman LLP as legal counsel, Future Pak is confident that it could finalize an agreement and announce a transaction within four to six weeks, provided it gains access to standard due diligence materials.

Founded in 1977, Future Pak is a privately held company specializing in contract manufacturing and packaging for the pharmaceutical and nutraceutical industries. The company's announcement is based on a press release statement. With Theratechnologies generating $88.67 million in revenue over the last twelve months and showing 13.52% growth, investors can access more detailed analysis through InvestingPro's comprehensive research reports, which offer expert insights on over 1,400 US stocks.

In other recent news, Theratechnologies Inc. has received FDA approval for the unrestricted distribution of its product EGRIFTA SV®, aimed at reducing excess abdominal fat in HIV-infected adults with lipodystrophy. This approval allows the company to resume regular distribution, closing a period of supply uncertainty. Additionally, the FDA has approved a new formulation, EGRIFTA WR™, which will replace EGRIFTA SV® in the U.S. market and offers a more convenient weekly dosing schedule. The new formulation has been highlighted for its potential to improve patient experience and is patent protected in the U.S. until 2033.

In another development, Theratechnologies presented promising study results for ibalizumab, used in combination antiretroviral therapy for patients with multidrug-resistant HIV. The study, presented at the Conference on Retroviruses and Opportunistic Infections, showed that ibalizumab-containing regimens achieved similar rates of viral suppression as non-ibalizumab regimens. The company continues to monitor patients in the ongoing study, highlighting its commitment to innovative therapies.

These developments reflect Theratechnologies' focus on advancing treatment options for HIV patients.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.